Jennifer Minoff, MD
Pulmonary Disease · Hannibal, MONPI 1013367101
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 67.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $7,088 and has fallen 81.4% since, to $1,320 in 2025.
Across 174 payments — averaging $54.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$669
- GSK$447
- Verona Pharma, Inc.$259
- Sanofi$233
- Viatris Specialty LLC$145
- plus $1K from 22 others
Across 2 payments — averaging $15,805 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$32K
What the payments were for
- Travel & lodging$2,36425%
- Food & beverage$2,99032%
- Education$4,11243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $6,401 |
| AstraZeneca | 36 | $669 |
| GSK | 33 | $447 |
| Verona Pharma, Inc. | 10 | $259 |
| Sanofi | 12 | $233 |
| Viatris Specialty LLC | 3 | $145 |
| Electromed, Inc. | 15 | $138 |
| Regeneron Healthcare Solutions, Inc. | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Grifols USA, LLC | 8 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Boehringer Ingelheim | 5 | $88 |
| Mylan Specialty L.p. | 5 | $85 |
| La Jolla Pharmaceutical Company | 1 | $79 |
| Amgen | 1 | $64 |
| Insmed, Inc. | 4 | $62 |
| Novartis | 3 | $53 |
| AbbVie | 2 | $40 |
| Pulmonx Corporation | 2 | $31 |
| Philips North America LLC | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Bayer | 2 | $29 |
| Vifor Pharma, Inc. | 1 | $25 |
| Merck | 1 | $18 |
| Biomerieux Inc | 1 | $16 |
| Ambu Inc. | 1 | $16 |
| Ceribell, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,285
- GLASSIA$125
- Ohtuvayre$125
- Yupelri$113
How this compares
$9,467 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 241 | $236,511 |
| OfevNintedanib Esylate | 13 | $182,233 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $115,026 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 86 | $74,443 |
| Spiriva RespimatTiotropium Bromide | 64 | $55,044 |
| NucalaMepolizumab | 13 | $45,078 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $29,526 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $23,427 |
| DuleraMometasone/Formoterol | 39 | $23,141 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $20,119 |
| Spiriva HandihalerTiotropium Bromide | 30 | $17,046 |
| EliquisApixaban | 21 | $14,673 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $10,846 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $8,190 |
| Roflumilast | 86 | $6,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $447 | $358,337370 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $88 | $253,787101 claims |
| Grifols USA, LLCProlastin C | $124 | $115,02613 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $669 | $77,83699 claims |
| MerckDulera | $18 | $23,14139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Hannibal
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Bobby ShahChesterfield$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.